Dr Phil McElnay is the CEO of MedAll - the virtual training platform for healthcare professionals
MedAll is on a mission to make great healthcare training accessible to every healthcare professional - everywhere. The company enables healthcare organizations to deliver and share their virtual and hybrid training content online with healthcare professionals around the world.
Using MedAll, healthcare professionals can learn the breadth of medicine in a single place from hundreds of healthcare organizations.
In 18 months, MedAll has powered healthcare training sessions for over 1400 organizations across 20+ countries. In that timeframe, its platform has been used by one third of UK medical students and one fifth of UK postgraduate trainee doctors to attend teaching and training sessions - as well as healthcare professionals in over 170 countries.
The company has been featured in the BBC, RTE, The Irish Times and Sifted/Financial Times, where it was described as one of “Europe’s hottest start-ups" and a "breakout start up of 2021"
Before MedAll Phil was a National Institute for Health Research Academic Clinical Fellow in Cardiothoracic Surgery. He has sat on the executive of the UK Association of Surgeons in Training as honorary secretary and international committees at the European Society of Thoracic Surgery and European Respiratory Society. He continues to be a member of the Royal College of Surgeons of England and was awarded an MSc with first-in-class distinction in clinical research from Newcastle University for his work on a significant minimally invasive cardiac surgery trial. In 2016 was appointed as Global Medical Director in Rare Diseases at GlaxoSmithKline where he was the medical lead for an innovative therapy which was subsequently approved by the FDA and EMA. He has authored or co-authored 30+ papers, 2 books and international guidelines for the European Respiratory Society.